Rebiotix Inc., a Ferring Company, is seeking to change the therapeutic landscape with our innovative microbiota-based MRT™ Drug Platform
The Rebiotix microbiota-based MRT drug platform, represents an entirely new approach to the treatment of challenging diseases by delivering live, human-derived microbes into a sick patient’s intestinal tract.
With our MRT™ drug platform, we have the possibility to change the therapeutic landscape for challenging diseases including recurrent Clostridium difficile (C. diff.) infection and more.
Harnessing the Power of the Microbiome for Challenging Diseases
The human gut microbiota, found in the intestinal tract, is the most diverse and dense microbial community. It plays an important role with metabolism and immunity.
Download the infographic. (7.6 MB)
